The article discusses serotype replacement in pneumococcal disease following pneumococcal vaccination, particularly with the 7-valent pneumococcal conjugate vaccine (PCV7). PCV7 has significantly reduced pneumococcal disease in many populations, but concerns remain about non-vaccine serotypes (NVTs) increasing in prevalence. While NVTs have increased in asymptomatic carriers, there has been little net change in carriage prevalence. In many populations, NVTs have increased in disease, but this increase has been less than the increase in NVT carriage. The article reviews evidence for serotype replacement in carriage and disease, addresses surveillance biases, and discusses possible reasons for the discrepancy between complete replacement in carriage and partial replacement in disease. It suggests that the magnitude of serotype replacement in disease may be due to lower invasiveness of replacing serotypes, biases in pre-vaccine carriage data, and biases in disease surveillance systems. The article concludes that serotype replacement in disease is a potential concern, and ongoing surveillance is needed. It also discusses the potential for serotype replacement in disease in the future and the need for continued monitoring. The article also addresses the impact of PCV7 in developing countries, the role of vaccination in increasing NVTs, and the importance of monitoring disease incidence and carriage patterns. It concludes that while PCV7 has had a significant positive impact on reducing pneumococcal disease in many populations, there is a need for continued surveillance to monitor for serotype replacement and to ensure the vaccine's long-term effectiveness.The article discusses serotype replacement in pneumococcal disease following pneumococcal vaccination, particularly with the 7-valent pneumococcal conjugate vaccine (PCV7). PCV7 has significantly reduced pneumococcal disease in many populations, but concerns remain about non-vaccine serotypes (NVTs) increasing in prevalence. While NVTs have increased in asymptomatic carriers, there has been little net change in carriage prevalence. In many populations, NVTs have increased in disease, but this increase has been less than the increase in NVT carriage. The article reviews evidence for serotype replacement in carriage and disease, addresses surveillance biases, and discusses possible reasons for the discrepancy between complete replacement in carriage and partial replacement in disease. It suggests that the magnitude of serotype replacement in disease may be due to lower invasiveness of replacing serotypes, biases in pre-vaccine carriage data, and biases in disease surveillance systems. The article concludes that serotype replacement in disease is a potential concern, and ongoing surveillance is needed. It also discusses the potential for serotype replacement in disease in the future and the need for continued monitoring. The article also addresses the impact of PCV7 in developing countries, the role of vaccination in increasing NVTs, and the importance of monitoring disease incidence and carriage patterns. It concludes that while PCV7 has had a significant positive impact on reducing pneumococcal disease in many populations, there is a need for continued surveillance to monitor for serotype replacement and to ensure the vaccine's long-term effectiveness.